Neurology · AnxiolyticRegulatory Approvalregulatorymid-term

Baxter Healthcare's Diazepam ANDA219882 Receives Approval Status

Importance7/ 10

ActionMonitor

AutoResearch

Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.

Last run 8/1/2026, 12:31:08 PM

Assessment confidence: 59% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.

Executive Thesis

Baxter Healthcare's approval status for Diazepam signifies a new entrant in a competitive market, which could disrupt existing pricing and market share dynamics. Pharma strategy teams must evaluate the implications of this approval on their portfolios and competitive positioning. Regulatory context from FDA (FDA AP — DIAZEPAM (ORIG)) supports the near-term read. Assessment grounded in 20 ranked evidence items (6 high-relevance).

Strategic Assessment

Portfolio teams should assess the impact of Baxter's entry on market share and pricing strategies for Diazepam. The strongest clinical anchor is The Effect of Channa Striata and Curcuma Supplementation on Nutritional Status, Interleukin-6 Levels, and Quality of Life in Patients With Breast Cancer. In Neurology · Anxiolytic, 6 regulatory and 6 competitive items passed relevance filtering for Diazepam.

Competitive Pressure

The most relevant competitive pressure comes from Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis (Humanexa Signals) — sponsor/company relevance (roche). Secondary pressure from Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217). This approval status indicates Baxter's entry into the Diazepam market, potentially increasing competition against existing generic and branded products.

Regulatory Outlook

Regulatory risk is concentrated around FDA AP — DIAZEPAM (ORIG) (FDA). Entity match (diazepam); Regulatory pathway relevance (nda). Relevant agencies in corpus: FDA, MHRA. The approval status indicates that Baxter is on track for market entry, necessitating close monitoring of the final approval and launch timeline to assess compliance and market readiness.

Key Risks

Elevated medium regulatory exposure for Diazepam could delay market entry or constrain labeling if agency review intensifies.

Key Opportunities

The entry of Baxter into the Diazepam market may lead to increased competition, affecting pricing strategies and potentially impacting revenue for existing players.
Upside for Diazepam may improve if Perceptions, knowledge, and access to the HPV vaccine among parents and healthcare providers in South Quito, Ecuador in 2025: A qualitative study. (PubMed) delivers favorable follow-through.
Portfolio teams should assess the impact of Baxter's entry on market share and pricing strategies for Diazepam.

What Would Change This Assessment

This becomes more urgent if Monitor for the final approval and market launch timeline for ANDA219882.
Additional medium- or high-relevance evidence would materially upgrade this assessment.
Timeline shift beyond mid term would change urgency.
A competitor label expansion or pivotal readout in the same sub-indication would increase competitive pressure.

Supporting Evidence

FDA AP — DIAZEPAM (ORIG)
FDAhigh relevance
Entity match (diazepam); Regulatory pathway relevance (nda)
FDA document
View source
FDA AP — DIAZEPAM (ORIG)
FDAhigh relevance
Entity match (diazepam); Regulatory pathway relevance (nda)
FDA document
View source
Advancing Generic Drug Development: Leveraging Model-Integrated Evidence (MIE) in the Development & Approval of Generic Drugs - 08/27/2026
FDAhigh relevance
Regulatory pathway relevance (approval)
FDA document
View source
Corporate report: Medicines and Healthcare Products Regulatory Agency Annual Report and Accounts 2025 to 2026
MHRAmedium relevance
Moderate corpus alignment
FDA document
View source
Transparency data: Medicines and Healthcare products Regulatory Agency Privacy Notice
MHRAmedium relevance
Moderate corpus alignment
FDA document
View source
Policy paper: Medicines and Healthcare products Regulatory Agency (MHRA) economic growth goals
MHRAmedium relevance
Moderate corpus alignment
FDA document
View source

The Effect of Channa Striata and Curcuma Supplementation on Nutritional Status, Interleukin-6 Levels, and Quality of Life in Patients With Breast Cancer.
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Relationship Between Clinical Status and Nerve Conduction Test Findings in Patients With Unilateral Hemiplegia
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Hydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Menstrual Status, Anesthetic Consumption, and PONV
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source
Dynamic Auditory Cueing for Spatial Neglect in Stroke
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View source

Roche's Elecsys® pTau217 Blood Test Receives CE Mark for Alzheimer's Diagnosis
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Roche receives CE mark for new blood test to detect Alzheimer's pathology: Elecsys® plasma phosphorylated-tau 217 (pTau217)
Rochehigh relevance
Sponsor/company relevance (Roche)
FDA document
View source
Teva's Sugammadex Sodium Receives FDA Approval Status
Humanexa Signalsmedium relevance
Moderate corpus alignment
Dr. Reddy's Sugammadex Sodium ANDA214236 Receives FDA Approval
Humanexa Signalsmedium relevance
Moderate corpus alignment
Sandoz Receives FDA Approval for Sugammadex Sodium (ANDA214311)
Humanexa Signalsmedium relevance
Moderate corpus alignment

Perceptions, knowledge, and access to the HPV vaccine among parents and healthcare providers in South Quito, Ecuador in 2025: A qualitative study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Cost-effectiveness of multitarget stool DNA testing for colorectal cancer screening in Chinese primary healthcare settings: a modelling study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source
Effects of acute HMB-FA supplementation on antioxidant status and muscle damage in Elite Judoka: a randomized pilot trial.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View source

Regunera

Precedents · guidance

Reg

Loading regulatory precedents…

View full regulatory analysis

Competitiva

Competitors · threats

Intel

Loading competitive findings…

View full competitive analysis

Why this matters

Affected entities

Diazepam

Commercial impact

medium

The entry of Baxter into the Diazepam market may lead to increased competition, affecting pricing strategies and potentially impacting revenue for existing players.

Regulatory impact

medium

The approval status indicates that Baxter is on track for market entry, necessitating close monitoring of the final approval and launch timeline to assess compliance and market readiness.

What to watch

Monitor for the final approval and market launch timeline for ANDA219882.

Recommended action

Monitor

Track for follow-up milestones; no immediate action required.